This can lead to more complications, such as: Acute pancreatitis can have a mortality rate of up to 2%, but this can be much higher for severe cases. With the SIRS, the mortality rate rises to 25%.

Enrollment ongoing in Phase 2 KOURAGE trial of AuxoraTM in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of ...

About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's ...

Cash, cash equivalents, and short-term investments were $18.7M as of December 31, 2024, which, combined with the net proceeds of $9.7M from the ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

is a rare but distinct subtype of chronic pancreatitis. AIP is best described as the pancreatic manifestation of a systemic fibroinflammatory conditions. The systemic disease of which AIP is a ...

Richard Paolone, CEO of Entero, commented, "After completion of our internal review, we determined that executing the Rescission Agreement was the best option for Entero and our shareholders.